Vertex Pharmaceuticals (VRTX) Price Target Upgraded at Summer Street Research

Vertex Pharmaceuticals (VRTX) received a “buy” rating reiteration today from investment firm Summer Street Research.  Summer Street also increased their price target for VTRX a substantial amount from $46 to $72 dollars.  VTRX is currently trading above its 50 & 200-day moving averages and 2011 is currently an up year for the company.

Vertex Pharmaceuticals in the business of discovering, developing and commercializing small molecule drugs for the treatment of serious diseases. In November 2010, they submitted a new drug application, or NDA, requesting approval to market telaprevir in the United States for the treatment of patients with chronic hepatitis C virus, or HCV, infection.  The company has market capitalization of $11,036,000,000 and 204,413,000 shares outstanding.  VTRX has a 52-week high of $58.87 with the low being $31.25 dollars.



Latest News

DAO.Casino Market Cap Reaches $1.77 Million
DAO.Casino Market Cap Reaches $1.77 Million
Cannation Price Hits $0.0014
Cannation Price Hits $0.0014
Liberty Braves Group Series C  and pdvWireless  Head to Head Analysis
Liberty Braves Group Series C and pdvWireless Head to Head Analysis
Allianz  versus Its Peers Head-To-Head Review
Allianz versus Its Peers Head-To-Head Review
Traders Sell iShares iBoxx $ High Yield Corporate Bond ETF  on Strength
Traders Sell iShares iBoxx $ High Yield Corporate Bond ETF on Strength
Investors Sell Shares of Elanco Animal Health  on Strength
Investors Sell Shares of Elanco Animal Health on Strength


© 2006-2019 Ticker Report